Aclaris Therapeutics (ACRS) Net Margin (2017 - 2025)
Historic Net Margin for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to 464.69%.
- Aclaris Therapeutics' Net Margin fell 2695600.0% to 464.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 922.44%, marking a year-over-year decrease of 7811300.0%. This contributed to the annual value of 705.48% for FY2024, which is 4223300.0% down from last year.
- According to the latest figures from Q3 2025, Aclaris Therapeutics' Net Margin is 464.69%, which was down 2695600.0% from 922.34% recorded in Q2 2025.
- In the past 5 years, Aclaris Therapeutics' Net Margin ranged from a high of 10.57% in Q4 2023 and a low of 1702.25% during Q2 2023
- Over the past 5 years, Aclaris Therapeutics' median Net Margin value was 987.17% (recorded in 2021), while the average stood at 871.15%.
- Its Net Margin has fluctuated over the past 5 years, first tumbled by -15871200bps in 2021, then surged by 13050700bps in 2024.
- Over the past 5 years, Aclaris Therapeutics' Net Margin (Quarter) stood at 1525.18% in 2021, then skyrocketed by 75bps to 375.07% in 2022, then soared by 97bps to 10.57% in 2023, then crashed by -9917bps to 1059.3% in 2024, then skyrocketed by 56bps to 464.69% in 2025.
- Its Net Margin stands at 464.69% for Q3 2025, versus 922.34% for Q2 2025 and 1094.02% for Q1 2025.